Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: Caffeine for Hypoxic-Ischemic Encephalopathy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating caffeine for hypoxic-ischemic encephalopathy has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Caffeine (caffeine)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Hypoxic-Ischemic Encephalopathy | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19